Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include common findings: Aortic rupture and Ascending aortic dissection; and sometimes findings: Descending aortic dissection and Sudden death. 5 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 4 | Aortic rupture, Descending aortic dissection, Ascending aortic dissection |
Age of onset: adulthood.
MYLK encodes myosin light chain kinase (1,914 aa). Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contraction via phosphorylation of myosin light chains (MLC). Highest expression in Esophagus Muscularis (441.2 TPM) and Colon Sigmoid (430.1 TPM).
Aortic aneurysm, familial thoracic 7 is associated with mutations in the MYLK gene on chromosome 3.
The MYLK protein participates in MYLK (MLCK) Active Calmodulin Binding pathway.
MYLK is classified as a druggable target (Druggable Genome, Enzyme, Kinase, and Serine Threonine Kinase categories) with score 3.5.
Genetic testing for MYLK is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for aortic aneurysm, familial thoracic 7 has been reported in the published literature.
Phenotype severity distribution: 2 common features.
No clinical trials have been registered for aortic aneurysm, familial thoracic 7.
153 publications have been identified in PubMed for aortic aneurysm, familial thoracic 7. Research spans Basic Science / Preclinical (27%), Epidemiology / Natural History (20%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 42 | 27% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 7:49 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Disease patterns and progression
31 |
20% |
Research summaries | 28 | 18% |
Clinical study results | 17 | 11% |
New treatment approaches | 14 | 9% |
Testing and diagnosis research | 9 | 6% |
Patient case studies | 8 | 5% |
Other research | 4 | 3% |
Hu YN (2026). [PMID: 41611116](https://pubmed.ncbi.nlm.nih.gov/41611116/). *Biochimica et biophysica acta. Molecular basis of disease*. [Review / Meta-Analysis]
Liu L (2026). [PMID: 41487086](https://pubmed.ncbi.nlm.nih.gov/41487086/). *Circulation*. [Basic Science / Preclinical]
Rios JL (2026). [PMID: 41265988](https://pubmed.ncbi.nlm.nih.gov/41265988/). *Heart failure clinics*. [Basic Science / Preclinical]
Stougiannou TM (2026). [PMID: 42195012](https://pubmed.ncbi.nlm.nih.gov/42195012/). *Genes (Basel)*. [Review / Meta-Analysis]
Schwarz EL (2026). [PMID: 42113285](https://pubmed.ncbi.nlm.nih.gov/42113285/). *Biomech Model Mechanobiol*. [Basic Science / Preclinical]
Yamaoka M (2026). [PMID: 40803860](https://pubmed.ncbi.nlm.nih.gov/40803860/). *Internal medicine (Tokyo, Japan)*. [Case Report / Case Series]
Hayashi N (2026). [PMID: 41773057](https://pubmed.ncbi.nlm.nih.gov/41773057/). *Vasc Med*. [Clinical Trial Publication]
Yonekawa J (2026). [PMID: 41739588](https://pubmed.ncbi.nlm.nih.gov/41739588/). *J Clin Invest*. [Basic Science / Preclinical]
He H (2026). [PMID: 41260386](https://pubmed.ncbi.nlm.nih.gov/41260386/). *Life sciences*. [Basic Science / Preclinical]
Takahashi K (2026). [PMID: 41596218](https://pubmed.ncbi.nlm.nih.gov/41596218/). *Int J Mol Sci*. [Review / Meta-Analysis]